Company news
Creative Medical Technology Holdings, Inc. news in 2024
Creative Medical Technology Holdings, Inc.'s news releases, calls and decks from 2024, newest first.
Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment
November 12, 2024
Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
October 22, 2024
Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program
July 23, 2024
Creative Medical Technology Holdings Provides Corporate Update
July 9, 2024
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin
June 23, 2024
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
March 6, 2024
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
March 5, 2024